Middle East Pharmaceutical Industries Company

4016.SRSAUHealthcare● Active

$62.10

$-0.20(-0.32%)

Market Cap$2.2B

P/E Ratio—

52W High$79.08572

52W Low$53.88572

Avg Volume188K

Open$62.40

Beta0.48

Cash on Hand Financials Revenue

Middle East Pharmaceutical Industries Company (4016.SR) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

4016.SR · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$34.4M▲ +51.8% vs prior year

FY · as of Dec 31, 2025 · Reported in SAR

Cash & Cash Equiv. (CCE)

$34.4M

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+51.8%

vs prior fiscal year

Latest Quarter

$18.8M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in SAR

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$34.4MCash on Hand

Total Debt$63.8MTotal Debt

Net Cash / Net Debt−$29.5MNet Debt Position

Cash vs Debt Ratio

Cash 35%Middle East Pharmaceutical Industries Company cash as % of market cap: 1.58%% · MCap $2BDebt 65%

Middle East Pharmaceutical Industries Company carries a net debt position of $29.5M. Total debt ($63.8M) exceeds cash on hand ($34.4M). Middle East Pharmaceutical Industries Company cash vs debt ratio: 35% cash / 65% debt.

Net Cash = Cash & ST Investments − Total Debt$34.4M − $63.8M = −$29.5M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

4016.SR annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

4016.SR cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$34.4M+51.8%

Dec 31, 2024FY$22.6M+49.9%

Dec 31, 2023FY$15.1M-36.5%

Dec 31, 2022FY$23.8M+25.0%

Dec 31, 2021FY$19.0M+19.5%

4016.SR cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

4016.SR vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Middle East Pharmaceutical Industries CompanyYOU

4016.SR

$34.4M$2B1.6%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Middle East Pharmaceutical Industries Company (4016.SR) cash on hand as of December 31, 2025 is $34.4M, comprising $34.4M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Middle East Pharmaceutical Industries Company cash and short-term investments on the balance sheet (10-K filing). Also referred to as Middle East Pharmaceutical Industries Company cash reserves or cash position.

Middle East Pharmaceutical Industries Company annual cash on hand history shows increased +51.8% in 2025: increased +51.8% in 2025. Middle East Pharmaceutical Industries Company cash reserves in 2025 reflect the company's capital allocation strategy.

Middle East Pharmaceutical Industries Company carries total debt of $63.8M against cash of $34.4M, resulting in a net debt position of -$29.5M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

4016.SR cash on hand · 5 questions

As of December 31, 2025, Middle East Pharmaceutical Industries Company (4016.SR) has $34,370,454 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $34,370,454 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $18,818,641. Data sourced from the annual 10-K filing via FMP.

4016.SR cash on hand4016.SR cash reserves4016.SR cash 2025how much cash does 4016.SR have

▸ Source: FMP /balance-sheet-statement · US GAAP · Middle East Pharmaceutical Industries Company · Middle East Pharmaceutical Industries Company SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025